|
|
|
| Meta-analysis of efficacy and safety of Xingxiong Sodium Chloride Injection in the treatment of ischemic stroke |
| YU Zecheng1 LUO Xiaodong2 CAI Qiaodi1 ZHENG Chunye2 |
1.The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510405, China;
2.Department of Neurology, Fangcun Branch, Guangdong Hospital of Traditional Chinese Medicine, Guangdong Province, Guangzhou 510370, China |
|
|
|
Abstract Objective To systematically evaluate the efficacy and safety of Xingxiong Sodium Chloride Injection in the treatment of ischemic stroke. Methods Systematic search of PubMed, CNKI, Wanfang database, Vip, SinoMed and other databases was conducted to collect randomized controlled trials (RCT) of Xingxiong Sodium Chloride Injection in the treatment of ischemic stroke. The retrieval time was from the establishment of the database to December 2018. Data was extracted by two professionals and merged and analyzed by RevMan 5.3 software. The quality of the included literature were evaluated using the risk assessment form provided by the collaborative network. Results There were 9 RCTs and 1511 patients, including 756 in experimental group and 755 in control group. Results of Meta-analysis: total effective rate of drug treatment in experimental group was higher than that in control group [RR = 1.11, 95%CI (1.01, 1.22), P = 0.04]. The improvement of neurological deficit in experimental group was better than that in control group [MD = -4.16, 95%CI (-7.23, -1.10), P = 0.008]. There was no significant difference in Barthel index score between two groups [MD = -0.39, 95%CI (-17.29, 16.50), P = 0.96]. The level of hs-CRP in experimental group was lower than that in control group [MD = -1.94, 95%CI (-3.38, -0.51), P = 0.008]. Conclusion Xingxiong Sodium Chloride Injection is effective and safe in the treatment of ischemic stroke. However, there is still a lack of more reliable clinical trials to provide clinical evidence.
|
|
|
|
|
|
[1] Fonarow GC，Zhao X，Smith EE，et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative [J]. JAMA，2014，311（16）：1632-1640.
[2] Sturm JW，Dewey HM，Donnan GA，et al. Handicap after stroke：how does it relate to disability，perception of recovery，and stroke subtype? the north North East Melbourne Stroke Incidence Study （NEMESIS） [J]. Stroke，2002，33（3）：762.
[3] 冯宇飞，王春虎.黄煌经方沙龙从少阳论治脑卒中医案一则浅解[J].光明中医，2015，30（10）：2074-2075.
[4] 全国第四次脑血管学术会议.各类脑血管疾病诊断要点[J].中华神经科杂志，1996，29（6）：379.
[5] 全国第四次脑血管学术会议.脑卒中患者临床神经功能缺损程序评分标准（1995）[J].中华神经科杂志，1996，29（6）：381.
[6] 陈波，罗俊超，王朝阳.银杏达莫注射液对急性脑梗死患者血清MMP-9和hs-CRP的影响[J].中医药信息，2016， 33（1）：69-71.
[7] 赵玫，张漫.缺血性脑卒中患者急性期C反应蛋白水平与病情及预后的相关性分析[J].中国实用神经疾病杂志，2006，9（2）：18-20.
[8] 左平祥，高瑞利，季向东，等.急性脑梗死患者血清CRP含量动态变化及临床相关性研究[J].临床合理用药杂志，2009，2（18）：1-2.
[9] 高路，李旭东，南佳彦，等.短暂性脑缺血发作患者血清高敏-C反应蛋白的水平变化与脑血栓形成的关系[J].中国急救医学，2003，23（7）：30-32.
[10] 李建标，何锦照，钟小劲，等.杏芎氯化钠注射液联合丁苯酞对急性脑梗死认知障碍患者神经及认知功能的影响[J].国际医药卫生导报，2018，24（12）：1835-1838.
[11] 卢金华，程熙，赖靖慧.杏芎氯化钠注射液治疗缺血性脑卒中疗效观察[J].中国实用神经疾病杂志，2018，21（2）：147-149.
[12] 郑文鑫，董学爽，朱春雨，等.杏芎氯化钠注射液治疗缺血性脑卒中的临床效果[J].中国现代药物应用，2018， 12（23）：70-71.
[13] 江铮，张龙滨.杏芎氯化钠注射液治疗急性脑梗死临床观察[J].中国实用神经疾病杂志，2018，21（1）：44-46.
[14] 杨丽英.杏芎氯化钠注射液治疗缺血性脑卒中疗效观察[J].医学信息，2010，5（4）：943-944.
[15] 赵焕东，王秀芝，万新立，等.杏芎氯化钠注射液治疗256例脑梗死的临床疗效研究[J].实用全科医学，2007（9）：809-810.
[16] 杨文波，孙玉琴.杏芎氯化钠注射液治疗急性脑梗塞32例临床观察（英文）[J].时珍国医国药，2007，18（8）：2063-2064.
[17] 田丽川，武志忠.美托康治疗急性脑梗塞50例疗效观察[J].现代保健·医学创新研究，2006，3（11）：236.
[18] 李卫林，王新立，刘建国，等.杏芎氯化钠注射液治疗缺血性脑卒中的临床研究[J].临床医药实践，2006，15（12）：901-902.
[19] 李玉琼.银杏叶提取物对短暂性脑缺血发作患者血液流变学及神经功能的影响[J].中国疗养医学，2018，27（8）：790-792.
[20] 濮琦琳，于雪峰，朱燕，等.川芎嗪注射液对大鼠急性脊髓损伤后脊髓组织中MDA和SOD水平的影响[J].今日药学，2017，27（2）：96-98.
[21] 李蓓.56例丹参川芎嗪注射液不良反应/事件分析[J].中国药物评价，2013，30（3）：159-160，164. |
|
|
|
